Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825512 | Clinical Therapeutics | 2014 | 13 Pages |
Abstract
Adding canagliflozin treatment to healthy participants on HCTZ treatment had no notable pharmacokinetic or pharmacodynamic effects; canagliflozin coadministered with HCTZ was generally well tolerated, with no unexpected tolerability concerns. ClinicalTrials.gov identifier: NCT01294631.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Damayanthi PhD, Nicole BS, David PhD, Sarah MSc, Ewa MD, PhD,